[go: up one dir, main page]

FR15C0049I1 - Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1 - Google Patents

Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1

Info

Publication number
FR15C0049I1
FR15C0049I1 FR15C0049C FR15C0049I1 FR 15C0049 I1 FR15C0049 I1 FR 15C0049I1 FR 15C0049 C FR15C0049 C FR 15C0049C FR 15C0049 I1 FR15C0049 I1 FR 15C0049I1
Authority
FR
France
Prior art keywords
receptor antagonists
phenylpyridine derivatives
phenylpyridine
derivatives
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR15C0049I1 publication Critical patent/FR15C0049I1/fr
Application granted granted Critical
Publication of FR15C0049I2 publication Critical patent/FR15C0049I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
FR15C0049C 1999-02-24 2015-07-08 Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1 Active FR15C0049I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29
EP00102260A EP1035115B1 (fr) 1999-02-24 2000-02-15 Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1

Publications (2)

Publication Number Publication Date
FR15C0049I1 true FR15C0049I1 (fr) 2015-08-28
FR15C0049I2 FR15C0049I2 (fr) 2016-02-12

Family

ID=26152908

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0002170A Expired - Fee Related FR2790473B1 (fr) 1999-02-24 2000-02-22 Nouveaux composes et medicaments les contenant
FR15C0049C Active FR15C0049I2 (fr) 1999-02-24 2015-07-08 Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0002170A Expired - Fee Related FR2790473B1 (fr) 1999-02-24 2000-02-22 Nouveaux composes et medicaments les contenant

Country Status (54)

Country Link
US (2) US6297375B1 (fr)
EP (2) EP1394150B1 (fr)
JP (1) JP3399900B2 (fr)
KR (1) KR100384904B1 (fr)
CN (1) CN1142144C (fr)
AR (2) AR029614A1 (fr)
AT (2) ATE496032T1 (fr)
AU (1) AU767048B2 (fr)
BE (1) BE2015C057I2 (fr)
BG (1) BG64554B1 (fr)
BR (1) BRPI0000908B8 (fr)
CA (1) CA2299139C (fr)
CY (3) CY1111317T1 (fr)
CZ (1) CZ300596B6 (fr)
DE (3) DE60014216T2 (fr)
DK (2) DK1035115T3 (fr)
EA (1) EA003673B1 (fr)
EG (1) EG23817A (fr)
ES (3) ES2226622T3 (fr)
FR (2) FR2790473B1 (fr)
GB (1) GB2347422A (fr)
GE (1) GEP20022676B (fr)
GT (1) GT200000017A (fr)
HR (2) HRP20000097B1 (fr)
HU (1) HU227629B1 (fr)
IL (1) IL134654A (fr)
IS (1) IS2116B (fr)
IT (1) IT1320763B1 (fr)
JO (1) JO2294B1 (fr)
LT (1) LTC1035115I2 (fr)
LU (1) LU92745I2 (fr)
MA (1) MA26722A1 (fr)
ME (1) ME00593B (fr)
MY (2) MY147451A (fr)
NL (1) NL300758I2 (fr)
NO (1) NO315554B1 (fr)
NZ (1) NZ502948A (fr)
OA (1) OA11680A (fr)
PA (1) PA8491101A1 (fr)
PE (1) PE20001467A1 (fr)
PL (1) PL217311B1 (fr)
PT (2) PT1394150E (fr)
RS (3) RS20080562A (fr)
SE (1) SE1035115T5 (fr)
SG (1) SG91856A1 (fr)
SI (1) SI1035115T1 (fr)
SK (2) SK287912B6 (fr)
SV (1) SV2002000024A (fr)
TN (1) TNSN00032A1 (fr)
TR (1) TR200000520A3 (fr)
TW (1) TWI288746B (fr)
UA (1) UA71547C2 (fr)
UY (1) UY32314A (fr)
ZA (1) ZA200000894B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (fr) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Ct-1, un oncogene humain
WO2000050398A2 (fr) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
BRPI0116121B8 (pt) 2000-12-14 2021-05-25 F Hoffmannn La Roche Ag composição de matriz de lipídeo auto-emulsificante para administração oral e seu processo de preparação
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
DK1385577T3 (da) * 2001-04-23 2006-08-21 Hoffmann La Roche Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
ES2357808T3 (es) * 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
CA2457250C (fr) * 2001-09-10 2010-03-30 F. Hoffmann-La Roche Ag Formulations thixotropes huileuses
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
WO2004026823A1 (fr) 2002-09-20 2004-04-01 Pfizer Products Inc. Ligands d'amides et de sulfonamides du recepteur oestrogenique
WO2004052291A2 (fr) 2002-12-06 2004-06-24 Purdue Research Foundation Pyridines destinees au traitement de tissus nerveux mammaliens leses
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
WO2004067007A1 (fr) * 2003-01-31 2004-08-12 F. Hoffmann-La Roche Ag Nouvelle modification cristalline de 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1?6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridine-3-yl]-n-methyl-isobutyramide
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
TWI345974B (en) 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
CN1997371A (zh) * 2004-07-06 2007-07-11 泽农医药公司 烟酰胺衍生物及其作为治疗剂的用途
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
CN1984891B (zh) * 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
WO2006013205A1 (fr) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Antagonistes des récepteurs de la neurokinine-1 pour le traitement des états sensibles à une élévation de la testostérone
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP1830837B1 (fr) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Derives heterocycliques pour le traitement de maladies induites par des enzymes stearoyl-coadesaturases
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2006060174A1 (fr) * 2004-11-15 2006-06-08 Honeywell International Inc. Mousses polymeres a base d'isocyanate avec des materiaux a nano-echelle
US7176205B2 (en) * 2005-02-22 2007-02-13 Hoffmann-La Roche Inc. Bi-pyridinyl derivatives as NK-1 antagonists
CN101128428A (zh) * 2005-02-24 2008-02-20 詹森药业有限公司 作为钾离子通道打开剂的新的吡啶衍生物
EP2281556A1 (fr) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Comprimés avec une meilleure dispersibilité de substance des médicaments
BRPI0609699A2 (pt) * 2005-03-23 2010-04-20 Hoffmann La Roche metabolitos para antatonistas de nk-1 para êmese
EP2029138A1 (fr) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
KR20080053297A (ko) * 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
US7683056B2 (en) 2005-09-09 2010-03-23 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
WO2007039420A1 (fr) * 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Nouvelle forme galénique
DK2774925T3 (en) 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2882684T3 (es) 2006-04-07 2021-12-02 Vertex Pharma Preparación de moduladores de transportadores del casete de unión a ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN103626744B (zh) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
AU2008335440B2 (en) * 2007-12-07 2013-11-07 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
IN2012DN01292A (fr) * 2009-08-27 2015-06-05 Glaxosmithkline Llc
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
AR081069A1 (es) 2010-04-07 2012-06-06 Vertex Pharma Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico
EP2555755B2 (fr) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
WO2011133920A1 (fr) 2010-04-23 2011-10-27 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2013019635A1 (fr) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et méthodes
WO2013019621A1 (fr) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et méthodes
PT2744497T (pt) 2011-10-18 2016-07-18 Helsinn Healthcare Sa Combinações terapêuticas de antiemético e quimioterapia induzida
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
RU2673084C2 (ru) * 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
PT3131582T (pt) 2014-04-15 2018-10-08 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
WO2015171489A1 (fr) * 2014-05-05 2015-11-12 Apicore Us Llc Procédés de fabrication de nétupitant et d'intermédiaires de celui-ci
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
KR102860817B1 (ko) 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
WO2017044693A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
KR20180090302A (ko) * 2015-12-07 2018-08-10 깃세이 야쿠힌 고교 가부시키가이샤 Nk1 수용체 길항제
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) * 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
EA202090180A1 (ru) 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019038656A1 (fr) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd Nouvelles formulations à triple combinaison pour une thérapie antiémétique
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
WO2020132716A1 (fr) * 2018-12-24 2020-07-02 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Fabrication d'un composé chimique, nouvelle forme de sel, et utilisations thérapeutiques associées
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
AU2020337177B2 (en) * 2019-08-23 2025-06-26 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
IL296635A (en) 2020-04-03 2022-11-01 Nerre Therapeutics Ltd An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385500A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes comprenant du nétupitant et du palonosétron
EP4385497A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
EP4633608A1 (fr) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Association de dose fixe sans antioxydant de netupitant et de palonosétron
AU2023393578A1 (en) 2022-12-12 2025-07-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
EP0089765A3 (fr) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Dérivés de pyridine
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (fr) 1988-09-14 1997-09-02 Yuji Ono Pyridines et leur emploi en pharmacie
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
KR100286412B1 (ko) 1993-12-29 2001-04-16 더블유. 지. 콜 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JPH10501228A (ja) 1994-06-06 1998-02-03 ワーナー−ランバート・コンパニー タキキニン（ｎｋ▲下１▼）受容体アンタゴニスト
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
TW394773B (en) * 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
CA2250372C (fr) 1996-03-29 2005-06-21 Pfizer Inc. Derives de 6-phenylpyridyl-2-amines
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
WO2000050398A2 (fr) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives

Also Published As

Publication number Publication date
SV2002000024A (es) 2002-01-23
HRP20000097A2 (en) 2001-10-31
PL217311B1 (pl) 2014-07-31
MY147451A (en) 2012-12-14
GB0003908D0 (en) 2000-04-05
ES2171109A1 (es) 2002-08-16
JO2294B1 (en) 2005-09-12
HU227629B1 (en) 2011-10-28
PT1394150E (pt) 2011-02-17
DE10008042A1 (de) 2000-08-31
GB2347422A (en) 2000-09-06
ATE496032T1 (de) 2011-02-15
EP1035115A1 (fr) 2000-09-13
BG104187A (en) 2000-11-30
BR0000908A (pt) 2000-09-12
NL300758I1 (fr) 2015-12-22
EA200000155A3 (ru) 2000-12-25
HRP20000097B1 (en) 2008-12-31
US6297375B1 (en) 2001-10-02
CZ300596B6 (cs) 2009-06-24
TR200000520A2 (tr) 2001-06-21
TNSN00032A1 (fr) 2005-11-10
DE60045564D1 (de) 2011-03-03
NL300758I2 (fr) 2015-12-22
ITMI20000328A0 (it) 2000-02-23
HUP0000748A3 (en) 2003-12-29
BRPI0000908B8 (pt) 2021-05-25
BE2015C057I2 (fr) 2019-03-06
IT1320763B1 (it) 2003-12-10
BG64554B1 (bg) 2005-07-29
PT1035115E (pt) 2005-01-31
HU0000748D0 (en) 2000-04-28
GEP20022676B (en) 2002-04-25
NO20000885L (no) 2000-08-25
KR20000062599A (ko) 2000-10-25
AR062949A2 (es) 2008-12-17
HRP20080306B1 (hr) 2015-01-30
RS50194B (sr) 2009-05-06
AR029614A1 (es) 2003-07-10
EP1035115B1 (fr) 2004-09-29
FR2790473A1 (fr) 2000-09-08
EP1394150A1 (fr) 2004-03-03
IL134654A0 (en) 2001-04-30
MY123648A (en) 2006-05-31
MEP5709A (en) 2011-12-20
UY32314A (es) 2010-02-26
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (sr) 2015-08-31
NO20000885D0 (no) 2000-02-23
SI1035115T1 (en) 2005-02-28
DK1035115T3 (da) 2005-01-24
GT200000017A (es) 2001-08-15
ZA200000894B (en) 2000-08-24
CY2015041I2 (el) 2016-06-22
TR200000520A3 (tr) 2001-06-21
PA8491101A1 (es) 2001-04-30
EP1394150B1 (fr) 2011-01-19
DE60014216T2 (de) 2006-03-02
IL134654A (en) 2011-03-31
DE60014216D1 (de) 2004-11-04
CN1270959A (zh) 2000-10-25
ES2359235T3 (es) 2011-05-19
ES2226622T3 (es) 2005-04-01
UA71547C2 (uk) 2004-12-15
ME00593B (me) 2015-08-31
FR2790473B1 (fr) 2004-04-02
AU1946800A (en) 2000-08-31
ATE277905T1 (de) 2004-10-15
TWI288746B (en) 2007-10-21
IS2116B (is) 2006-06-15
EA003673B1 (ru) 2003-08-28
HRP20080306A2 (en) 2008-11-30
MA26722A1 (fr) 2004-12-20
EA200000155A2 (ru) 2000-08-28
SE1035115T3 (sv) 2005-01-18
JP3399900B2 (ja) 2003-04-21
US20020091265A1 (en) 2002-07-11
SK287912B6 (sk) 2012-03-02
CA2299139C (fr) 2011-03-29
DK1394150T3 (da) 2011-03-21
CY2015041I1 (el) 2016-06-22
SE1035115T5 (sv) 2015-08-04
ES2171109B2 (es) 2003-09-16
HUP0000748A2 (en) 2001-03-28
NO315554B1 (no) 2003-09-22
AU767048B2 (en) 2003-10-30
CA2299139A1 (fr) 2000-08-24
FR15C0049I2 (fr) 2016-02-12
EG23817A (en) 2007-09-19
YU9500A (sh) 2002-11-15
KR100384904B1 (ko) 2003-05-22
SG91856A1 (en) 2002-10-15
CN1142144C (zh) 2004-03-17
OA11680A (fr) 2005-01-12
PL338598A1 (en) 2000-08-28
US6479483B2 (en) 2002-11-12
SK287911B6 (sk) 2012-03-02
BR0000908B1 (pt) 2013-09-24
LU92745I2 (fr) 2015-08-17
ITMI20000328A1 (it) 2001-08-23
CY1111317T1 (el) 2015-08-05
RS20080562A (sr) 2009-09-08
LTC1035115I2 (lt) 2017-04-10
SK2352000A3 (en) 2000-09-12
PE20001467A1 (es) 2000-12-20
CZ2000609A3 (cs) 2001-01-17
IS5381A (is) 2000-08-25
NZ502948A (en) 2001-09-28
JP2000247957A (ja) 2000-09-12
CY2015042I1 (el) 2016-06-22
HK1031223A1 (en) 2001-06-08

Similar Documents

Publication Publication Date Title
FR15C0049I2 (fr) Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
FR13C0001I2 (fr) Derives de quinuclidine et leur utilisation comme ligands des recepteurs m3 muscariniques
FR17C1056I1 (fr) Pd-1, recepteur de b7-4, et son utilisation
IL144851A0 (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
MA26762A1 (fr) Derives de pyrrolidine- antagonistes du recepteur ccr-3
EP0880511A4 (fr) Antagonistes du recepteur integrine
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
ATE312089T1 (de) Vitronektin rezeptor antagonisten
DE60118569D1 (de) 4-phenylpyridin-derivate als neurokinin-1-rezeptor-antagonisten
ATE305920T1 (de) Bradykinin receptorantagoniste
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001515D0 (no) Vitronektin reseptor-antagonist
MA26907A1 (fr) Cyclohexylamines bicycliques et leur utilisation comme antagonistes de recepteurs de nmda.
NO971136D0 (no) Aminoalkyl- og acylaminoaklyleter, fremgangsmåte for fremstilling derav og anvendelse som bradykinin-reseptor antagonister
EP1248607A4 (fr) Antagonistes des recepteurs de l'urotensine ii
ATE196766T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
DE69920518D1 (de) Vitronectin rezeptor antagonist
EP0912182A4 (fr) Promedicaments antagonistes du recepteur de fibrinogene
ATE228514T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
EP1023295A4 (fr) Promedicaments antagonistes de recepteur de fibrinogene
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
EP0781133A4 (fr) Antagonistes du recepteur de fibrinogene
GB9708766D0 (en) Fibrinogen receptor antagonist
HUP9901033A3 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists